BioCryst Pharmaceuticals

(NASDAQ) BCRX

Current Price$8.96

Market Cap$2.29B

Since IPO (1994)+39%

5 Year-30%

1 Year-12%

1 Month-4%

BioCryst Pharmaceuticals Financials at a Glance

Market Cap

$2.29B

Revenue (TTM)

$885.72M

Net Income (TTM)

$457.98M

EPS (TTM)

$-1.78

P/E Ratio

-5.08

Dividend

$0.00

Beta (Volatility)

1.10 (Average)

Dividend

$0.00

Beta (Volatility)

1.10 (Average)

Price

$8.96

Volume

116,339

Open

$9.01

Price

$8.96

Volume

116,339

Open

$9.01

Previous Close

$8.96

Daily Range

$8.76 - $9.04

52-Week Range

$6.00 - $11.31

Dividend

$0.00

Beta (Volatility)

1.10 (Average)

Price

$8.96

Volume

116,339

Open

$9.01

Previous Close

$8.96

Daily Range

$8.76 - $9.04

52-Week Range

$6.00 - $11.31

BCRX News

Page 1

BCRX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioCryst Pharmaceuticals

Industry

Biotechnology

Sector

Health Care

Employees

435

CEO

Charles K. Gayer, MBA

Website

www.biocryst.com

Headquarters

Durham, NC 27703, US

BCRX Financials

Key Financial Metrics (TTM)

Gross Margin

19%

Operating Margin

-43%

Net Income Margin

-52%

Return on Equity

Return on Capital

-1%

Return on Assets

-98%

Earnings Yield

-19.69%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.29B

Shares Outstanding

254.16M

Volume

116.34K

Avg. Volume

5.50M

Financials (TTM)

Gross Profit

$855.76M

Operating Income

$340.99M

EBITDA

$347.65M

Operating Cash Flow

$329.88M

Capital Expenditure

$2.47M

Free Cash Flow

$327.41M

Cash & ST Invst.

$274.75M

Total Debt

$477.33M

BioCryst Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$156.41M

+7.5%

Gross Profit

$546.73M

-487.8%

Gross Margin

-3.50%

N/A

Market Cap

$2.29B

N/A

Market Cap/Employee

$3.95M

N/A

Employees

580

N/A

Net Income

$721.81M

-2255762.5%

EBITDA

$701.60M

-2954.0%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$618.83M

-15.9%

Accounts Receivable

$109.27M

+17.0%

Inventory

$5.99M

-12.9%

Long Term Debt

$814.67M

+2.8%

Short Term Debt

$43.41M

+16.8%

Return on Assets

-98.48%

N/A

Return on Invested Capital

-1.42%

N/A

Free Cash Flow

$62.54M

-126.1%

Operating Cash Flow

$62.14M

-125.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

TRVITrevi Therapeutics, Inc.

TRVITrevi Therapeutics, Inc.$13.43-5.42%

PHVSPharvaris N.V.

PHVSPharvaris N.V.$28.81-5.23%

STOKStoke Therapeutics, Inc.

STOKStoke Therapeutics, Inc.$29.03-3.49%

ZYMEZymeworks Inc.

ZYMEZymeworks Inc.$24.43+2.09%

ARDXArdelyx, Inc.

ARDXArdelyx, Inc.$6.11-1.93%

NTLAIntellia Therapeutics, Inc.

NTLAIntellia Therapeutics, Inc.$12.69-7.17%

MAZEMaze Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.$24.50-4.15%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$13.74-0.02%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$14.20-0.06%

TET1 Energy Inc.

TET1 Energy Inc.$7.00+0.23%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$74.32-0.01%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$43.54+0.01%

POETPoet Technologies

POETPoet Technologies$14.21-0.11%

FFord Motor Company

FFord Motor Company$13.03-0.03%

Questions About BCRX

What is the current price of BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals is trading at $8.97 per share.

What is the 52-week range for BioCryst Pharmaceuticals?

Over the past 52 weeks, BioCryst Pharmaceuticals has traded between $6.00 and $11.31.

How much debt does BioCryst Pharmaceuticals have?

As of the most recent reporting period, BioCryst Pharmaceuticals reported total debt of $858.08M.

How much cash does BioCryst Pharmaceuticals have on hand?

BioCryst Pharmaceuticals reported $172.44M in cash and cash equivalents in its most recent financial results.

What is BioCryst Pharmaceuticals’s dividend yield?

BioCryst Pharmaceuticals does not currently have a dividend yield.

BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Financials at a Glance

BCRX News

BioCryst (BCRX) Q2 Revenue Jumps 50%

Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today

Why BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday

Why BioCryst Pharmaceuticals Stock Is Soaring Today

Why Shares of BioCryst Pharmaceuticals Jumped Today

Why BioCryst Pharmaceuticals Stock Is Sinking Today

Got $3,000? Here Are 2 Stocks That Will Make You Richer

Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today

BCRX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About BioCryst Pharmaceuticals

BCRX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

BioCryst Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About BCRX

What is the current price of BioCryst Pharmaceuticals?

What is the 52-week range for BioCryst Pharmaceuticals?

How much debt does BioCryst Pharmaceuticals have?

How much cash does BioCryst Pharmaceuticals have on hand?

What is BioCryst Pharmaceuticals’s dividend yield?

Premium Investing Services